Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam Effects on Neuroimaging Measures
NCT04671836Phase 1Withdrawn
- Sponsor
- Northwell Health
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anxiety disorder comparing Lorazepam first with Placebo first (2 arms). Primary endpoint: Resting state functional magnetic imaging connectivity at 2 weeks. Planned start Jan 2022; status: withdrawn.
02
Drugs
lorazepam
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT04671836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671836.